Publicerat: 2022-05-23 11:51:13

Inhalation Sciences Q1’22: Eventful Start to 2022 - Redeye

Redeye comments on ISAB’s Q1’22 report. The company has seen a continued high interest for its IRS business during the first quarter and with a pending FDA approval for its white paper proposal submitted in January, the company has an interesting period ahead.

Länk till analysen

Läs mer om Inhalation Sciences Sweden AB